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BACKGROUND: Despite the plethora of research around the negative effects of diabetes on different body organs,
this topic still attracts a lot of attention to find potential remedies that could counteract or reverse the damaging effect
of diabetes.
AIM: In this study, we developed a reliable experimental rat model that can be used for the investigation of the ability
of epidermal growth factor (EFG) in restoring the normal architecture of oral tissues after being damaged by diabetes.
METHODS: Eighty adult male albino rats (average weight ±220 gm) were used in the current study. Twenty rats
served as control and received no treatment. Diabetes was induced in 40 rats using a single injection of 65 mg/kg of
streptozotocin. Out of the 40 diabetic rats, 20 rats received a single daily intraperitoneal injection of epidermal growth
factor (EGF) (10 µg/Kg) for 8 weeks. Furthermore, 20 healthy rats received the same dose of EGF and served as
positive controls. The submandibular salivary glands of all rats were examined for immunohistochemical detection
of myosin in the glandular structure.
RESULTS: The EGF-treated group showed comparable myosin expression to the control group. The diabetic group
revealed deterioration of all components of the submandibular salivary glands. Finally, the diabetic + EGF group has
demonstrated restoration of the myosin expression levels in the submandibular salivary glands to a level that is not
significantly different from healthy (nondiabetic) rats in the control group (p > 0.05) and significantly higher than the
diabetic group (p < 0.0001).
CONCLUSION: The findings of the present study confirm previous studies and validate the use of our animal model as
predictable experimental tool to investigate the effects of diabetes and EGF on different oral tissues. It also highlights
the importance of further research investigating EGF as a promising treatment modality for the restoration of the
condition and functions of tissues damaged by diabetes not only in the oral cavity but also around the whole body.

Introduction
Animal models provide a unique opportunity to
research to study the development of diseases and their
complication under controlled conditions that limits the
influence of genetic and environmental factors on the
progression of diseases, including diabetes [1], [2], [3], [4].
In diabetes research, different animal models have
been developed and used to study type I diabetes
by spontaneously developing autoimmune diabetes
or ablation of beta cells of the pancreas, while type II
diabetes animal models have different degrees of
obesity, insulin resistance, and pancreatic beta cells
failure [5], [6], [7]. Therefore, it has been recommended
to use multiple animal models in the study of diabetes
due to the great variability in individuals suffering from
diabetes within the human population [7].
Diabetes mellitus (DM), also known simply
as diabetes, is a group of metabolic diseases in
190

which there are high blood sugar levels over a
prolonged period [8]. It characterized by persistent
hyperglycemia, glucosuria, and polyuria [9].
This results in elevated blood glucose levels
(hyperglycemia), which leads to a number of
complications, including nephropathy, neuropathy,
cardiomyopathy,
retinopathy,
atherosclerosis,
microangiopathy, and diabetic foot ulcers [10].
Moreover, diabetes is associated with an increased
susceptibility to bacterial infections, inflammation,
caries, xerostomia, and periodontal diseases and is
also related with malfunctioning of salivary glands
resulting in deficient salivary flow [11].
Investigations demonstrated that insulin
and diabetes affect the function and structure of rat
parotid gland found that after 1 month, of diabetes
induction in rats, there was an inhibition glands
growth in diabetic rats [12], [13]. By histological
examination of the gland, there were an excessive
accumulation of lipid droplets within the acinar cells,
https://oamjms.eu/index.php/mjms/index



cytoplasm together with increase of lysosomes.
Moreover, it was found that dense vacuoles and
crystalloids were found in the apical cytoplasm of the
parotid gland striated duct cells [12], [13]. The effect
of diabetes on salivary flow and protein secretion by
salivary glands results in an increased susceptibility
to mucosal infections, tooth demineralization, and
caries [14]. It was concluded that reduced statherin
secretion by salivary glands in diabetic mice might
be partly responsible for a less effective protection
of the oral tissues, resulting in a higher incidence
of caries and oral infections associated with
diabetes [14].

Bakr et al. Effect of Epidermal Growth Factor on Salivary Glands of Diabetic Rats

Methods
Animals and housing
Eighty male Albino rats of adult age, 3 months
old (average weight 220 g), were used in this study.
Albino rats were sourced from Kasr ElAini experimental
animals’ unit, Faculty of Medicine, Cairo University,
were fed natural diet and supplied drinking water ad
libitum throughout the whole experimental period.
Experimental groups

Epidermal growth factor (EGF) is a powerful
protein that has a significant role in wound healing
through facilitating the proliferation and migration of
fibroblasts [15]. EGF was identified while studying
nerve growth factor in submaxillary glands of
male Swiss‑Webster mice. EGF is known to be
produced in human salivary glands [16]. EGF binds
specifically to its receptor, EFG receptor, which is
found on the surface of the cells. The high affinity
between the EGF and its receptor stimulates and
activates the intrinsic protein-tyrosine kinase activity
of the receptor [17]. This activation then starts a
signal transduction cascade which ends in various
biochemical alterations within the cell. These
changes include increase in protein synthesis and in
glycolysis as well as an increase in gene expression
which eventually leads to DNA synthesis and cell
proliferation [18].

The albino rats were divided equally (n = 20)
into four groups as follows:

Myosins include a family of ATP-dependent
motor proteins and are best known for their role in
muscle contraction and their involvement in a wide
range of other eukaryotic motility processes. They
are responsible for actin-based motility. The term was
originally used to describe a group of similar ATPases
found in striated and smooth muscle cells [19].
Myosins participate in a variety of cellular processes,
including cytokinesis, organellar transport, cell
polarization, transcriptional regulation, intracellular
transport, and signal transduction. They bind to
filamentous actin and produce physical forces by
hydrolyzing ATP and converting chemical energy into
mechanical force [20]. In a previous study that was
conducted by our research team, we showed that
cytokeratin was highly expressed in streptozotocin
(STZ)-induced diabetic rats treated with EGF. Myosin
being an integral component within the cytoskeleton
of the parenchymal elements of salivary glands helps
maintain its integrity.

Rats were subjected to a single injection of EFG
intraperitoneally in daily dose (EFG, human - animal
component free - recombinant, expressed in
Escherichia coli) provided by Sigma-Aldrich, Inc., in a
dose of 10 µg/Kg for 8 weeks [23].

The aim of the present study was to validate
the diabetes-EGF experimental rat model and to detect
if EGF could reduce the well-known side effects of DM
induced by STZ on the submandibular salivary gland
of adult male Albino rats or not. This was verified
through immunohistochemical detection of myosin in
the parenchyma of the gland.

Control group
Control group was injected with the same number
of saline injections that is equivalent to EGF injections.
Diabetic group
DM was induced by subjecting the rats a single
intraperitoneal injection of 65 mg/kg of freshly prepared
STZ (Sigma-Aldrich Co) dissolved in 0.1 M sodium
citrate buffer after subjecting the rats to 16-hr fasting
period prior to the STZ injection [21], [22].
Epidermal growth factor group

Diabetic + epidermal growth factor group
Rats were treated with STZ as the diabetic group
rats. After confirming their diabetic condition, they were
subjected to a single injection of EFG as per the EGF group.
At the end of the experiment, animals of all
groups were euthanized, and their submandibular
salivary glands were dissected.
Image and statistical analysis
Immunohistochemical detection of myosin was
performed in the glandular tissue using staining reaction
incubated by antimyosin antibody and color developed
by 3-Amino-9-ethylcarbazole (AEC) (Figure 1a). The
specimens were examined and photographed using
ZEISS Primo Starlight microscopy mounted by Tucsen
IS 1000 10.0MP Camera in the Centre of Innovative
dental sciences, Faculty of Dentistry, The British
University in Egypt.
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The myosin immunointensity in the glandular
specimens from different groups was analyzed using
Image J (1.46 a, NIH, USA) software. For each
selected section, 6 microscopic fields were captured at
a magnification ×200.
Statistical
analysis
of
the
myosin
immunoexpression was performed and described in
terms of mean and standard deviation. Analysis of
variance (ANOVA) test was used to compare groups
followed by independent samples test as post hoc for
two-group comparisons. All statistical analysis was
done using Statistical Package for the Social Sciences
version 28 (SPSS Inc., Chicago, IL, USA).

Results
Negative control
Submandibular salivary glands sections taken
from animals from the control group and incubated
with non-specific serum and color developed by
AEC showing no staining reaction for all glandular
components (Figure 1b).

a

b

Figure 1: (a) Showing an example of masking myosin expression by
red colour and the grey background with no immune reaction to Myosin.
(b) A photomicrograph of (control group) incubated with non-specific
serum and colour developed by AEC showing no staining reaction of
submandibular salivary gland elements (Original magnification, ×200).

Control group
Negative staining of the cytoplasm of mucous
secretory cells was evident in the EGF group. While
negative to weakly positive staining of the cytoplasm
opposite to the lumen and intercellular canaliculi of
serous secretory cells was observed in the same
group. Strongly positive staining reaction was found
around nearly all the secretory cells and intercalated
ducts representing staining of the myoepithelial cells
(MECs). The intercalated ducts, striated ducts, granular
convoluted tubules, and excretory ducts demonstrated
weakly positive staining reaction. Moderately to
strongly positive staining reaction was evident within
the vascular walls surrounding the excretory ducts and
connective tissue cells showed weakly positive staining
reaction (Figure 2a).
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Figure 2: A photomicrograph of a Submandibular salivary gland from
the incubated with antimyosin antibody and color developed by AEC.
(a) Control group showing weakly +ve reaction of serous acinar cells,
and strongly +ve reaction in myoepithelial cells. (b) Diabetic group
showing -ve to weakly +ve reaction of serous acinar cells, and weakly
+ve reaction in the myoepithelial cells. (c) Epidermal growth factor group
showing -ve to weakly +ve reaction of serous acinar cells, and strongly
+ve reaction in the myoepithelial cells. (d) Diabetic + epidermal growth
factor showing weakly +ve reaction of serous acinar cells, and strongly
+ve reaction in the myoepithelial cells. (Original magnification ×200)

Diabetic group
Negative staining of the cytoplasm of mucous
secretory cells. While negative to weakly positive staining
of the serous secretory cells. The MECs surrounding the
periphery of the acini and the intercalated ducts showed
weakly positive staining reaction in their cell bodies and
weaker staining reaction of their cell processes. The
intercalated ducts, striated ducts, granular convoluted
tubules, and excretory ducts revealed negative to weakly
positive staining reaction. The walls of blood vessels
presented weakly positive reaction as well as connective
tissue cells surrounding the excretory ducts (Figure 2b).
Epidermal growth factor group
Negative staining of the cytoplasm of mucous
secretory cells was evident in the EGF group. While
negative to weakly positive staining of the cytoplasm
opposite to the lumen and intercellular canaliculi of serous
secretory cells was observed in the same group. Strongly
positive staining reaction was found around the secretory
cells and intercalated ducts representing MECs’ staining.
The intercalated ducts, striated ducts, granular convoluted
tubules, and excretory ducts showed weakly positive
staining reaction. Moderately to strongly positive staining
reaction was detected in the walls of blood vessels
surrounding the excretory ducts while connective tissue
cells showed weakly positive staining reaction (Figure 2c).
Diabetic + epidermal growth factor group
Examination of sections taken from the
Diabetic rats treated with EFG and incubated with
https://oamjms.eu/index.php/mjms/index
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anti-myosin antibody revealed obvious improvements
in comparison to those of the diabetic group. Negative
staining of the cytoplasm of mucous secretory cells,
while negative to weakly positive staining reaction of
the cytoplasm was evident opposite to the lumen and
intercellular canaliculi of serous secretory cells.
The MECs with their elongated cell bodies and
the spider-like extensions of their processes showed
strongly positive staining reaction around nearly all the
secretory cells and intercalated ducts. The intercalated
ducts, striated ducts, granular convoluted tubules,
and excretory ducts revealed weakly positive staining
reaction. The walls of blood vessels represented
moderately to strongly positive reaction while connective
tissue cells showed weakly positive staining reaction.
Statistical results
Histomorphometric
analysis
of
the
submandibular salivary gland of the three groups
revealed that the highest mean area percent occupied
by myosin immunostaining was recorded in the control
group, whereas the lowest value was recorded in the
diabetic (Table 1). ANOVA test revealed a statistically
significant difference in the mean area percentage of
expression of myosin immunostaining (p < 0.0001).
Table 1: Mean values and standard deviation of the area
percentage of expression of myosin immunostaining in the
submandibular salivary glands of the different groups
Group
Number of cases
Maximum
Minimum
Mean ± SD

Control
20
33.24
31.41
30.72 ± 3.05

Diabetic
20
12.21
9.48
11.01 ± 1.59

EGF
20
35.87
32.14
31.86 ± 3.55

Diabetic + EGF
20
29.75
23.13
24.27 ± 3.95

SD: Standard deviation, EGF: Epidermal growth factor.

A pairwise comparison was held between
myosin mean area expression percentage in the control
group and the other experimental groups using an
independent t-test. A statistically significant decrease in
the myosin expression area percentage in the diabetic
group (p < 0.0001) and the diabetic + EGF (p<0.05)
when compared to the control group. There was no
statistically significant difference between the myosin
expression in the control and EGF groups. Furthermore,
there was a statically significant decrease in the myosin
expression area percentage in the Diabetic + EGF group
40
35
30
25
20
15
10
5
0

Control

Diabetic

EGF

Diabetic + EGF

Figure 3: Bar chart showing the mean myosin expression area
percentage in submandibular gland between all the groups
Open Access Maced J Med Sci. 2022 May 16; 10(D):190-196.

when compared to the control group (p<0.05). Finally,
there was a significant increase in myosin expression
area percentage in the EGF and the Diabetic + EGF
group when compared to the diabetic group (p < 0.0001)
(Figure 3).

Discussion
A successful choice of an animal model requires
careful consideration of a number of intrinsic and extrinsic
factors associated with disease being studied as well
as the similarities and differences between the humans
and the animal model in responding to the disease [24].
Procedural simplicity and reproducibility have been
identified as important criteria in an excellent animal
model [25], [26]. The animal model used in this study fulfills
the above requirements as it only involves two steps,
induction of diabetes and EGF injections. Furthermore,
the animal model should mimic the anatomy, histology
physiology, and genetics of humans [27]. The animal
model we used is ideal as rats have identical oral features
to humans [28], [29]. Immunohistochemical staining
of rodent salivary glands requires a careful choice of
secondary antibodies and negative control staining [29].
Therefore, a common immunohistochemical marker
(Mysoin) that is readily available in rats and human
salivary glands parenchyma/stroma as well as negative
control staining was performed.
STZ was the drug of choice in this study to
induce diabetes as it had low mortality rate and high
tolerance by the experimental animals than alloxan.
Furthermore, it can be given easily by different
routes, and its diabetogenic action was rapid and
permanent as it is known to destroy the beta cells of
islets of Langerhans [30]. Furthermore, for a functional
restoration of the damaged salivary glands, the diabetic
rats were treated with injection of EFG intraperitoneally
in daily doses for two months in accordance with that
used by Ohlsson et al., (1997) [22].
In the present study, different glandular
elements of the control animals stained positively
for myosin, these are the MECs, the serous acinar
cells and intercalated duct cells, assuming that these
contractile proteins might be involved in the process
of transport of cellular products and the exocytosis of
secretory granules. This finding is in agreement with
what has been reported by Ogawa (2003) [31] who
explained that contraction of the filaments helps to
expel the secretory granules towards the apical part
of the cells along the luminal border and opposite the
inter-canalicular spaces.
In the present investigation, the myosin was
demonstrated heavily in the MECs, pericytes as well as
smooth muscle cells of the blood vessels walls. Similar
findings were reported by (Dewar et al., 2011) [32]
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who found the same results on the MECs associated
with normal breast ductules and vascular smooth
muscle. In addition, these findings were concomitant
with Grandi et al., (2000) [33] who investigated
the immunocytochemical characteristics of normal
MECs of human major and minor salivary glands.
Immunoreactivity of MECs was observed exclusively
with fully differentiated smooth muscle antibodies.
The submandibular salivary glands of the
diabetic rats showed fainter staining patterns with
varying degrees (compared with the controls), denoting
a decrease in the intracellular content of myosin.
Furthermore, the defect in contraction of the MECs
due to the decrease in its myosin content may result in
impairment of the process of cytoplasmic exocytosis of
acinar cells and defective excretory function of the duct
system due to improper squeezing forces of the MECs,
making it not enough to clear the duct lumen. These
results were approved by histological and ultrastructural
findings in this investigation where the accumulation of
secretory granules in the acinar cells as well as most of
duct lumens which were dilated and filled with stagnant
secretion.
The production of EGF in the submandibular
gland and its circulating level were studied in diabetic
mice. EGF concentrations in the submandibular gland
and plasma were reduced to 13% and 30% of the control
levels, respectively. In STZ-treated diabetic mice, they
were reduced to 18% and 20% of controls, respectively,
5 weeks after the drug injection. In addition, histological
examination of the submandibular glands indicated
that the size of the granular convoluted tubules, which
produce EGF, was substantially reduced in the diabetic
mice. Insulin administration to STZ-treated mice almost
completely reversed the decrease in EGF content in
the submandibular gland and increased the size of
the granular convoluted tubules in the gland. It was
concluded that EGF deficiency occurs in DM and that
insulin may be important in maintaining the normal level
of EGF in the submandibular gland and plasma [34].
Salivary-derived growth factors, including
EFG, are known to play a major role in maintaining oral
health, promotion wound healing [35], and protecting
the mucosal integrity [36]. Salivary levels of EGF in
diabetic patients versus healthy controls were studied.
The salivary EGF concentration was significantly lower
for the diabetic patients compared to control patients
suggesting that reduced levels of salivary EGF in
diabetic patients may contribute to the development of
oral and systemic complications of diabetes, opening the
pathway for future clinical applications [9]. Furthermore,
the submandibular salivary gland under the effect of
induced DM was studied using routine hematoxylin
and eosin (H and E) stain, histopathologically for the
detection of carbohydrate using Periodic acid Schiff’s
(PAS) reaction and immunohistochemically for the
detection of anti-apoptotic marker, Beta cell lymphoma-2
(BCL) to investigate the DM effects and Vitamin C
194

Dental Pathology and Endodontics

(Ascorbic acid) on both the structure and function of
the submandibular salivary gland. The obtained results
revealed tissue alterations and common complications
in the submandibular glands of diabetic rats. On the
other hand, the antioxidant (Vitamin C)-treated rats
had less tissue alterations and lesions than untreated
animals [37].
The remarkable feature of the results of the
present study is that it demonstrates the total or subtotal
prevention of diabetic changes in the submandibular
salivary gland by treatment with EFG. This is in
agreement with previous studies in the literature that
investigated the effects of EGF on different tissues
in diabetic patients [38], [39], [40], [41], [42], [43].
In addition to the above, previous studies using the
same experimental rat animal model revealed results
that are consistent with the present study [44], [45].
EGF restored normal cytokeratin expression [44] and
the ultrastructural picture of submandibular salivary
glands in diabetic rats [45]. The consistency in results
validates the use of our diabetes-EGF experimental
rat model in future studies involving other oral tissues
as well as different body organs. The simplicity,
ease of development, and predictability of reliable
outcomes encourages further studies that could
involve restoration of taste functions, delaying the
progression of periodontal disease, and counteracting
diabetes-induced xerostomia (dry mouth) using EGF.
Furthermore, combined therapeutic methods, including
the use of EGF and silver nanoparticles (AgNPs) [46] in
the management of diabetic would healing and healing
of dental extraction sockets will also be studied using
our experimental rat model. In general, treatment with
EGF is very promising. Before moving to the next level
of clinical trials, further studies are necessary to provide
more data related to the cost-effectiveness, best route
of administration, and optimal dosage before EGF can
be approved in regular clinical practice.

Conclusion
The experimental rat model described in the
current study is a simple, reliable, and predictable
animal model that can be used in diabetes and EGF
research. EFG administration in a daily dose of
10 µg/Kg body weight for 2 months intraperitoneally
leaded in the enhancement of all of the submandibular
salivary glands components. This was proven by
immunohistochemical localization of myosin. The
findings from the present study confirm previous results
from studies that used scanning electron microscopy
and cytokeratin expression and the same animal model.
https://oamjms.eu/index.php/mjms/index
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